Rhode Island’s Medicaid program is contemplating an end to coverage for GLP-1 drugs prescribed for weight loss. The proposal ...

Dr. Troy Mensen is a family medicine doctor based in the Chicago area. He completed his undergraduate degree at the University of Northern Iowa and his doctorate at Des Moines University College of ...

Demand for GLP-1 drugs is causing spending on traditional drugs to grow at a faster clip than spending on specialty drugs, according to new research. That could put further stress on employers and ...

Discover how GLP-1 drugs like Ozempic and Mounjaro are transforming the fight against obesity. Learn the science, the risks, and the real-world results from experts on the front lines. Take control of ...

The average cost of employer-sponsored health insurance climbed to $16,501 per employee in 2024, up 5% from the previous year, according to results from Mercer’s 2024 National Survey of ...

The US Food and Drug Administration (FDA) has instructed all GLP-1 drug-makers to update their warning labels to include the risk of serious kidney injury that can result from dehydration. This comes ...

Dr. Angela Fitch, co-founder and chief medical officer of knownwell, a "weight-inclusive" healthcare company based in Boston, said she would caution against labeling any medication as an "everything ...

Scientists have discovered a possible association between popular drugs such as Ozempic and an increased risk of damage to the kidneys, pancreas and the digestive system. Weight-loss medications ...

Consider safety when combining GLP-1 medications with preexisting digestive health conditions. GLP-1 medications are prescribed to lower blood sugar levels in people with type 2 diabetes. They’re also ...

A new study published by Cleveland Clinic researchers in Diabetes, Obesity and Metabolism investigating the genetic underpinnings of weight loss response has identified a gene, neurobeachin (NBEA), as ...

For patients with idiopathic intracranial hypertension (IIH), glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is associated with improved clinical outcomes compared with conventional ...